at Pennsylvania State U

ow nloaded from doi:10.1016/j.ehj.2003.12.024.duction with pravastatin treatment was 27 % for major coronary events (95 % CI 8–42%), 27 % for coronary heart disease mortality (95 % CI 0–47%), 21 % for all-cause mortality (95 % CI 0–38%), and 51 % for stroke (95 % CI 24–69%). The number needed to treat to prevent a major coronary event over 6 years was 22. Conclusions Treatment with pravastatin in patients with both low LDL-C and low HDL-C significantly reduced major coronary events, stroke, and all-cause mortality. The level of HDL-C is crucial to the risk of recurrent CHD events and, consequently, th